Jerry C. Griffin - Mar 18, 2024 Form 4 Insider Report for Inspire Medical Systems, Inc. (INSP)

Role
Director
Signature
/s/ Bryan Phillips, as Attorney-in-Fact for Jerry C. Griffin
Stock symbol
INSP
Transactions as of
Mar 18, 2024
Transactions value $
-$91,216
Form type
4
Date filed
3/20/2024, 05:51 PM
Previous filing
Mar 13, 2024
Next filing
Mar 27, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction INSP Common Stock Options Exercise $16K +1K +10.26% $16.00* 10.7K Mar 18, 2024 Direct
transaction INSP Common Stock Sale -$10.5K -54 -0.5% $193.53 10.7K Mar 18, 2024 Direct F1
transaction INSP Common Stock Sale -$96.8K -500 -4.68% $193.53 10.2K Mar 18, 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction INSP Stock Option (Right to Buy) Options Exercise $0 -1K -43.55% $0.00 1.3K Mar 18, 2024 Common Stock 1K $16.00 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Reflects shares sold to cover taxes upon the option exercise pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 30, 2023 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
F2 The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 30, 2023 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
F3 The option is fully vested and exercisable.